Novetide expends its production plant

In order to cope with the increasing demand for peptide APIs, Novetide expands its production plant.

"We are pleased to offer our customers Novetide's top class facilities and expertise in peptide API capabilities," says Dr. Avi Tovi, Novetide's CEO. "The expansion of our capacity and capabilities in cGMP peptide APIs manufacturing emphasizes Novetide's commitment to its customers. It significantly increases our large scale manufacturing capacity and enables us the implementation of the challenges we are facing".